ATAI — ATAI Life Sciences NV Income Statement
0.000.00%
Last trade - 00:00- $1.38bn
- $1.29bn
- $0.31m
Annual income statement for ATAI Life Sciences NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 20.4 | 0.233 | 0.314 | 0.308 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 105 | 157 | 144 | 127 | 96.3 |
| Operating Profit | -105 | -136 | -143 | -126 | -96 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -102 | -137 | -135 | -39.3 | -148 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -102 | -133 | -141 | -40.3 | -148 |
| Minority Interest | |||||
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -170 | -168 | -152 | -40.2 | -149 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -170 | -168 | -152 | -40.2 | -149 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.03 | -1.1 | -0.982 | -0.237 | -0.948 |
| Dividends per Share |